NO20084742L - Aziridinyl-epotilonforbindelser - Google Patents
Aziridinyl-epotilonforbindelserInfo
- Publication number
- NO20084742L NO20084742L NO20084742A NO20084742A NO20084742L NO 20084742 L NO20084742 L NO 20084742L NO 20084742 A NO20084742 A NO 20084742A NO 20084742 A NO20084742 A NO 20084742A NO 20084742 L NO20084742 L NO 20084742L
- Authority
- NO
- Norway
- Prior art keywords
- substituted
- aryl
- alkyl
- heteroaryl
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80836606P | 2006-05-25 | 2006-05-25 | |
| PCT/US2007/069736 WO2007140297A2 (en) | 2006-05-25 | 2007-05-25 | Aziridinyl-epothilone compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20084742L true NO20084742L (no) | 2008-12-16 |
Family
ID=38561739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20084742A NO20084742L (no) | 2006-05-25 | 2008-11-10 | Aziridinyl-epotilonforbindelser |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7872145B2 (es) |
| EP (1) | EP2041140B1 (es) |
| JP (1) | JP5249929B2 (es) |
| KR (1) | KR101413955B1 (es) |
| CN (1) | CN101495482B (es) |
| AR (1) | AR061181A1 (es) |
| AT (1) | ATE524477T1 (es) |
| AU (1) | AU2007267535B2 (es) |
| BR (1) | BRPI0712167A2 (es) |
| CA (1) | CA2655668C (es) |
| EA (1) | EA014872B1 (es) |
| ES (1) | ES2371111T3 (es) |
| HK (1) | HK1124335A1 (es) |
| IL (1) | IL195236A (es) |
| MX (1) | MX2008014735A (es) |
| NO (1) | NO20084742L (es) |
| NZ (1) | NZ572763A (es) |
| PE (1) | PE20080316A1 (es) |
| TW (1) | TWI383985B (es) |
| WO (1) | WO2007140297A2 (es) |
| ZA (1) | ZA200810022B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2152717A1 (en) | 2007-05-25 | 2010-02-17 | Bristol-Myers Squibb Company | Processes for making epothilone compounds and analogs |
| MX2012013100A (es) | 2010-05-18 | 2013-01-22 | Cerulean Pharma Inc | Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades. |
| CA2943228C (en) | 2014-03-20 | 2023-03-14 | Bristol-Myers Squibb Company | Stabilized fibronectin based scaffold molecules |
| SI3221346T1 (sl) | 2014-11-21 | 2020-11-30 | Bristol-Myers Squibb Company | Protitelesa vsebujoča modificirana težko konstantna območja |
| BR112017010110A2 (pt) | 2014-11-21 | 2018-01-30 | Bristol-Myers Squibb Company | anticorpos contra cd73 e usos do mesmo |
| US10406251B2 (en) | 2014-11-25 | 2019-09-10 | Bristol-Myers Squibb Company | PD-L1 binding polypeptides for imaging |
| ES2736106T3 (es) | 2015-03-10 | 2019-12-26 | Bristol Myers Squibb Co | Anticuerpos que se pueden conjugar mediante la transglutaminasa y conjugados producidos a partir de ellos |
| PE20180926A1 (es) | 2015-05-29 | 2018-06-08 | Bristol Myers Squibb Co | Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral (ox40) y sus usos |
| EP3733698A1 (en) | 2015-09-23 | 2020-11-04 | Bristol-Myers Squibb Company | Glypican-3 binding fibronectin based scafflold molecules |
| JP2018534283A (ja) * | 2015-10-16 | 2018-11-22 | ウィリアム マーシュ ライス ユニバーシティＷｉｌｌｉａｍ Ｍａｒｓｈ Ｒｉｃｅ Ｕｎｉｖｅｒｓｉｔｙ | エポシロン類似体、合成方法、処置方法、およびその薬物結合体 |
| CN108431034A (zh) | 2015-12-21 | 2018-08-21 | 百时美施贵宝公司 | 用于位点-特异性缀合的变体抗体 |
| AU2017228470A1 (en) | 2016-03-04 | 2018-08-30 | Bristol-Myers Squibb Company | Combination therapy with anti-CD73 antibodies |
| WO2018048975A1 (en) | 2016-09-09 | 2018-03-15 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment |
| KR102085798B1 (ko) | 2016-12-28 | 2020-03-06 | 주식회사 인투셀 | 베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물 |
| EP3630833A1 (en) | 2017-05-25 | 2020-04-08 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| WO2020112781A1 (en) | 2018-11-28 | 2020-06-04 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| SI3886914T1 (sl) | 2018-11-30 | 2023-06-30 | Bristol-Myers Squibb Company | Protitelo, ki vsebuje C-terminalni podaljšek lahke verige, ki vsebuje glutamin, njegove konjugate ter metode in uporabe |
| CN113544155A (zh) | 2018-12-12 | 2021-10-22 | 百时美施贵宝公司 | 经修饰用于转谷氨酰胺酶缀合的抗体、其缀合物以及方法和用途 |
| CN110563730B (zh) * | 2019-07-29 | 2022-03-25 | 江苏理工学院 | 高纯度n10-三氟乙酰蝶酸的制备方法 |
| WO2021055306A1 (en) | 2019-09-16 | 2021-03-25 | Bristol-Myers Squibb Company | Dual capture method for analysis of antibody-drug conjugates |
| CA3185968A1 (en) | 2020-07-13 | 2022-01-20 | Tony Lahoutte | Antibody fragment against folr1 |
| EP4079327A1 (en) * | 2021-04-22 | 2022-10-26 | Centaurus Polytherapeutics | Payloads for drug-conjugates and their use for treating cancer |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| WO1999020626A1 (en) | 1997-10-17 | 1999-04-29 | Purdue Research Foundation | Folic acid derivatives |
| US6399638B1 (en) * | 1998-04-21 | 2002-06-04 | Bristol-Myers Squibb Company | 12,13-modified epothilone derivatives |
| US6291684B1 (en) | 1999-03-29 | 2001-09-18 | Bristol-Myers Squibb Company | Process for the preparation of aziridinyl epothilones from oxiranyl epothilones |
| AUPQ014799A0 (en) | 1999-05-04 | 1999-05-27 | Access Pharmaceuticals Australia Pty Limited | Amplification of folate-mediated targeting to tumor cells using polymers |
| JP2004532888A (ja) * | 2001-06-01 | 2004-10-28 | ブリストル−マイヤーズ スクイブ カンパニー | エポチロン誘導体 |
| PL374528A1 (en) | 2002-07-31 | 2005-10-31 | Schering Aktiengesellschaft | New effector conjugates, process for their production and their pharmaceutical use |
| EP1572242B1 (en) | 2002-12-13 | 2014-04-16 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| WO2004069159A2 (en) * | 2003-01-27 | 2004-08-19 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
| DE602005003453T2 (de) | 2004-01-30 | 2008-09-25 | Bayer Schering Pharma Aktiengesellschaft | Neue effektor-konjugate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung |
| AU2005294214A1 (en) | 2004-10-07 | 2006-04-20 | Emory University | Multifunctional nanoparticles conjugates and their use |
-
2007
- 2007-05-24 AR ARP070102263A patent/AR061181A1/es not_active Application Discontinuation
- 2007-05-24 PE PE2007000648A patent/PE20080316A1/es not_active Application Discontinuation
- 2007-05-25 NZ NZ572763A patent/NZ572763A/en not_active IP Right Cessation
- 2007-05-25 CN CN200780028309XA patent/CN101495482B/zh not_active Expired - Fee Related
- 2007-05-25 WO PCT/US2007/069736 patent/WO2007140297A2/en active Application Filing
- 2007-05-25 US US11/753,785 patent/US7872145B2/en not_active Ceased
- 2007-05-25 CA CA2655668A patent/CA2655668C/en not_active Expired - Fee Related
- 2007-05-25 ES ES07762325T patent/ES2371111T3/es active Active
- 2007-05-25 BR BRPI0712167-9A patent/BRPI0712167A2/pt not_active IP Right Cessation
- 2007-05-25 TW TW096118882A patent/TWI383985B/zh not_active IP Right Cessation
- 2007-05-25 JP JP2009512317A patent/JP5249929B2/ja not_active Expired - Fee Related
- 2007-05-25 EA EA200802389A patent/EA014872B1/ru not_active IP Right Cessation
- 2007-05-25 AT AT07762325T patent/ATE524477T1/de not_active IP Right Cessation
- 2007-05-25 AU AU2007267535A patent/AU2007267535B2/en not_active Ceased
- 2007-05-25 KR KR1020087031405A patent/KR101413955B1/ko not_active IP Right Cessation
- 2007-05-25 MX MX2008014735A patent/MX2008014735A/es active IP Right Grant
- 2007-05-25 EP EP07762325A patent/EP2041140B1/en active Active
-
2008
- 2008-11-10 NO NO20084742A patent/NO20084742L/no not_active Application Discontinuation
- 2008-11-11 IL IL195236A patent/IL195236A/en not_active IP Right Cessation
- 2008-11-25 ZA ZA2008/10022A patent/ZA200810022B/en unknown
-
2009
- 2009-04-23 HK HK09103805.0A patent/HK1124335A1/xx not_active IP Right Cessation
-
2011
- 2011-04-18 US US13/089,067 patent/USRE42930E1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US7872145B2 (en) | 2011-01-18 |
| EP2041140A2 (en) | 2009-04-01 |
| ZA200810022B (en) | 2011-05-25 |
| EA200802389A1 (ru) | 2009-06-30 |
| CN101495482B (zh) | 2012-05-02 |
| EA014872B1 (ru) | 2011-02-28 |
| AU2007267535A8 (en) | 2011-06-09 |
| CN101495482A (zh) | 2009-07-29 |
| ATE524477T1 (de) | 2011-09-15 |
| HK1124335A1 (en) | 2009-07-10 |
| AU2007267535B2 (en) | 2012-07-05 |
| BRPI0712167A2 (pt) | 2012-08-28 |
| US20070276018A1 (en) | 2007-11-29 |
| ES2371111T3 (es) | 2011-12-27 |
| TWI383985B (zh) | 2013-02-01 |
| EP2041140B1 (en) | 2011-09-14 |
| JP2009538349A (ja) | 2009-11-05 |
| TW200815452A (en) | 2008-04-01 |
| NZ572763A (en) | 2010-08-27 |
| CA2655668A1 (en) | 2007-12-06 |
| AR061181A1 (es) | 2008-08-13 |
| USRE42930E1 (en) | 2011-11-15 |
| IL195236A0 (en) | 2009-08-03 |
| KR20090025266A (ko) | 2009-03-10 |
| AU2007267535A1 (en) | 2007-12-06 |
| IL195236A (en) | 2012-12-31 |
| KR101413955B1 (ko) | 2014-07-01 |
| WO2007140297A2 (en) | 2007-12-06 |
| CA2655668C (en) | 2013-02-26 |
| WO2007140297A3 (en) | 2008-01-31 |
| JP5249929B2 (ja) | 2013-07-31 |
| MX2008014735A (es) | 2009-02-12 |
| PE20080316A1 (es) | 2008-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20084742L (no) | Aziridinyl-epotilonforbindelser | |
| NO20071642L (no) | N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger | |
| NZ592533A (en) | METHOD FOR THE PREPARATION OF N-(5-CHLORO-2-PYRIDINYL)-2-[[4-[(DIMETHYLAMINO) IMINOMETHYL] BENZOYL] AMINO]-5-METHOXY-BENZAMIDE, A FACTOR Xa INHIBITOR | |
| CY1118199T1 (el) | Ενωσεις υποκατεστημενης πυραζολο[1,5] πυριμιδινης ως ενδιαμεσα στη συνθεση αναστολεων κινασης trk | |
| NO20084783L (no) | Syntese av acylaminoalkenylenamider nyttige som substans P antagonister | |
| PE20061490A1 (es) | Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1 | |
| NO20084302L (no) | 2-(syklisk amino)-pyrimidonderivater som TPK1-inhibitorer | |
| NO20091141L (no) | Pyrido (2,3-D) pyrimidinonforbindelser og deres anvendelse som P13 inhibitorer | |
| HRP20130653T1 (en) | Pyrrole compounds | |
| TW200722086A (en) | Compounds comprising an oxazole or thiazole moiety, processes for making them and their uses | |
| WO2010005692A3 (en) | Insecticidal cyclic carbonyl amidines | |
| AR057380A1 (es) | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos | |
| BRPI0606845A2 (pt) | derivados de (1,5-difenil-1h-pirazol-3-il)oxadiazol, o respectivo preparo e a respectiva aplicação em terapêutica | |
| TW200738684A (en) | Novel sulfated cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | |
| NO20064351L (no) | Caspaseinhibitorer og anvendelser derav | |
| MY148980A (en) | Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics | |
| HK1089746A1 (en) | Amino alcohol derivatives, pharmaceutical compositions containing the same, and use thereof | |
| NO20076145L (no) | Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav | |
| WO2008136444A1 (ja) | 縮合複素環誘導体 | |
| ATE478054T1 (de) | Benzimidazolderivate | |
| MX2010001566A (es) | Derivado de aminopirazolamida. | |
| NO20085317L (no) | Imidazoazepinonforbindelser | |
| AR077534A1 (es) | Derivados de isoxazol, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con el receptor gaba aalfa5 | |
| ATE488510T1 (de) | Heterocyclische derivate, deren herstellung und therapeutische verwendung | |
| TNSN07439A1 (en) | Derivatives of,4,5 - diarylpyrrole, preparation method thereof and use of same in therapeutics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |